Cargando…
Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia
BACKGROUND: The extent of short-acting Beta-2-agonist (β(2)-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia. METHODS: This cross-sectional s...
Autores principales: | Wang, Hao-Chien, Djajalaksana, Susanthy, Sharma, Latha, Theerakittikul, Theerakorn, Lim, Hui Fang, Yoo, Kwang Ha, Yu-Lin, Andrea Ban, Diaz, Dina V., Yang, Lala, Beekman, Maarten J.H.I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587767/ https://www.ncbi.nlm.nih.gov/pubmed/37869560 http://dx.doi.org/10.1016/j.waojou.2023.100823 |
Ejemplares similares
-
SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study
por: Avdeev, Sergey, et al.
Publicado: (2022) -
Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023) -
Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022) -
Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
por: Bateman, Eric D., et al.
Publicado: (2022) -
Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
por: Price, David, et al.
Publicado: (2022)